Achromobacter xylosoxidans Antimicrobial Therapy
For Achromobacter xylosoxidans infections, treatment must be guided by antimicrobial susceptibility testing, with trimethoprim-sulfamethoxazole (TMP-SMZ) or a fluoroquinolone (ciprofloxacin/levofloxacin) as preferred agents for susceptible isolates, while combination therapy with meropenem plus an aminoglycoside or fluoroquinolone should be used for severe infections or resistant strains.
Key Treatment Principles
Antimicrobial Selection Based on Susceptibility
A. xylosoxidans exhibits intrinsic resistance to multiple antibiotic classes 1:
- Most cephalosporins (including third-generation agents)
- Aztreonam
- Aminoglycosides (though some isolates remain susceptible)
- Increasingly acquiring carbapenem resistance via efflux pumps and metallo-β-lactamases
The cornerstone of therapy is obtaining cultures with susceptibility testing before finalizing treatment - empiric therapy should be broad initially, then de-escalated based on results 2.
First-Line Agents for Susceptible Isolates
For mild-to-moderate infections when susceptibility is confirmed:
- TMP-SMZ 160-800 mg twice daily (oral) or 5-10 mg/kg/day of TMP component (IV) 2
- Ciprofloxacin 500-750 mg twice daily (oral) or 400 mg every 12 hours (IV)
- Levofloxacin 750 mg daily (oral or IV)
Severe Infections or Bacteremia
For severe presentations including bacteremia, use combination therapy 3, 4:
Preferred regimen:
- Ciprofloxacin (doses above) PLUS Amikacin (15 mg/kg/day divided every 12-24 hours based on renal function)
Alternative regimen:
- Meropenem 1 g every 8 hours IV PLUS either a fluoroquinolone or aminoglycoside (if susceptible)
- Piperacillin-tazobactam 3.375 g every 6-8 hours IV (initial empiric therapy) 2, 4
Emerging Therapeutic Options
Cefiderocol shows promise as a novel siderophore cephalosporin with activity against A. xylosoxidans, though some heterogeneity in susceptibility exists 5, 1. This should be considered for salvage therapy in MDR/XDR cases when traditional options fail.
Eravacycline has been used in limited salvage situations 1.
Clinical Approach Algorithm
Step 1: Risk Stratification
- Immunocompromised host? (X-linked agammaglobulinemia, cystic fibrosis, transplant recipients) → Higher risk, requires aggressive therapy 2
- Severity assessment: Bacteremia, septic shock, or organ dysfunction → Combination therapy mandatory
Step 2: Empiric Therapy (Before Susceptibilities)
- Severe/bacteremic: Piperacillin-tazobactam 3.375 g IV every 6-8 hours OR meropenem 1 g IV every 8 hours
- Mild-moderate: Ciprofloxacin 500-750 mg PO twice daily OR TMP-SMZ 160-800 mg PO twice daily
Step 3: Targeted Therapy (After Susceptibilities)
- If susceptible to fluoroquinolones: Ciprofloxacin or levofloxacin monotherapy (mild cases) or plus aminoglycoside (severe cases)
- If carbapenem-susceptible: Meropenem-based combination for severe infections
- If MDR/XDR: Consider cefiderocol or combination with phage therapy (investigational) 6
Step 4: Duration
- Bacteremia: 7-14 days depending on source control and clinical response
- Skin/soft tissue: 7-10 days with clinical improvement 2
- Respiratory (CF patients): Often requires prolonged courses, 14-21 days minimum
Critical Pitfalls to Avoid
Do NOT use aminoglycoside monotherapy - intrinsic resistance is common despite in vitro susceptibility 1
Do NOT assume cephalosporin activity - most cephalosporins (including ceftriaxone, ceftazidime) are ineffective due to intrinsic resistance 1
Do NOT delay susceptibility testing - empiric coverage must be broad, but A. xylosoxidans resistance patterns are unpredictable 3, 1
Monitor for nephrotoxicity when using aminoglycosides, especially in combination regimens - therapeutic drug monitoring is essential 7
Consider immunoglobulin replacement in agammaglobulinemic patients as adjunctive therapy 2
Special Populations
Cystic fibrosis patients: Chronic colonization is common; treat only symptomatic infections with prolonged courses and consider inhaled antibiotics for maintenance 1
Immunocompromised hosts: Always use combination therapy and ensure adequate immune reconstitution when possible 2
Post-surgical infections: Source control (drainage, debridement) is mandatory alongside antibiotics 4